Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 13/20 | 0.49 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745105 | 1.00 | VCAM1 (0.49) | VCAM1GRM8GRM6GRM4MEN1 | |
| SCHEMBL241620 | 0.87 | GRM8 (0.53) | VCAM1GRM8GRM6GRM4MEN1 | |
| SCHEMBL237370 | 0.87 | GRM8 (0.53) | VCAM1GRM8GRM6GRM4MEN1 | |
| SCHEMBL12727085 | 0.87 | GRM8 (0.53) | VCAM1GRM8GRM6GRM4MEN1 | |
| SCHEMBL1987819 | 0.87 | GRM8 (0.53) | VCAM1GRM8GRM6GRM4MEN1 | |
| SCHEMBL6743654 | 0.86 | VCAM1 (0.50) | VCAM1GRM8GRM6GRM4MEN1 | |
| SCHEMBL6743195 | 0.86 | VCAM1 (0.50) | VCAM1GRM8GRM6GRM4MEN1 | |
| SCHEMBL27819517 | 0.84 | GRM8 (0.51) | VCAM1GRM8GRM6GRM4MEN1 | |
| SCHEMBL6741460 | 0.83 | ALDH1A1 (0.45) | GRM8GRM6GRM4MEN1KMT2A | |
| SCHEMBL6746791 | 0.83 | ALDH1A1 (0.45) | GRM8GRM6GRM4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-04-25 | — | — | US | disclosed |
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-04-25 | — | — | US | disclosed |
| WO-2019053428-A1 | BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019053428-A1 | BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| EP-3426239-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153737-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153737-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2017-09-14 | — | — | WO | disclosed |
| US-6696573-B1 | SYNTHESIS OF SUCH AS 2-(N-(2-(9H-CARBAZOL-2-YLOXY)ETHYL))-AMINO-1-((3 -METHYLSULFONYLAMINO)PHENYL)ETHANOL WITH ENHANCED OPTICAL PURITY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2004-02-24 | — | — | US | disclosed |
| US-20030225289-A1 | Process for the preparation of tricyclic amino alcohol derivatives | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-12-04 | — | — | US | disclosed |
| CN-1377342-A | Process for preparation of tricyclic amino alcohol derivatives | ASAHI CHEMICAL IND (JP) | 2002-10-30 | — | — | CN | disclosed |
| EP-1209150-A1 | PROCESSES FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225289-A1 | Process for the preparation of tricyclic amino alcohol derivatives | ADH1A, ADH1C, OXER1 | VCAM1 1771/4885GRM8 4423/4885GRM6 4630/4885 |
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | SLC5A2, SLC5A1, SLC2A2 | VCAM1 4249/4885GRM8 3019/4885GRM6 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.